Sep 16, 2025
8:30 AM10:00 AM
Online
Oral Communication
Oral Communications VI: Nutrition Across Populations and Conditions: Innovative Approaches and Emerging Evidence
Cristian CobilinschiDileep LOBO
O068 - WEIGHT GAIN IS A GAIN IN LEAN BODY MASS AFTER INTRODUCTION OF THE CFTR MODULATORS IN CYSTIC FIBROSIS PATIENTS
O068
WEIGHT GAIN IS A GAIN IN LEAN BODY MASS AFTER INTRODUCTION OF THE CFTR MODULATORS IN CYSTIC FIBROSIS PATIENTS
Y. Rekioua1, T. Blin2, T. Flament2, S. Marchand-Adam2,3, J. Mankikian2, A. De Luca1,4,*
1Nutrition unit, 2CRCM, University Hospital, 3University, 4Inserm U1069, Tours, France
Rationale: Cystic fibrosis is associated with an increased risk of undernutrition. CFTR modulators aim to restore the function of the mutated protein. According to the literature, this treatment improves respiratory function and a weight gain has been observed. Our aim was to characterise the weight gain and the potential changes in body composition in the 12 months following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapies.
Methods: We conducted an observational, prospective, single-centre study, in the cystic fibrosis centre for adults of our University Hospital. Inclusion criteria were age ≥18 years old, one F508del mutation at least in the CFTR gene, and initiation of ETI treatment. No advice on physical activity was given. We monitored weight, body composition (bioelectrical impedance analysis), grip strength and dietary survey at 0, 3, 6 and 12 months after the introduction of treatment.
Results: We included 24 patients. Mean age was 30±8 years, mean Forced Expiratory Volume (FEV1) was 60±24%. The weight gain at 12 months was +4 kg (57±8 vs. 61±9 kg, +7%, p<10-3), the body mass index gain was +1.3 kg/m² (21.1±2.6 vs. 22.4±2.8 kg/m², p<10-4), with a significant gain in lean body mass of +3 kg (45±7 vs. 48±8 kg, p<10-3), the variation in fat mass was not significant. The weight gain was mostly during the first 3 months (p<10-4), in a lesser extend during the following 3 months (p=0.04), and then remained unchanged up to 12 months. A gain in grip strength was observed: right hand +9.7% (+3.2 kg, p=0.005), left hand +14.8 % (+4.4 kg, p=10-3). Food intake was not significantly different.
Conclusion: Our study showed that weight gain after introduction of CFTR modulators was around +7%, mainly in the first 3 months, with a gain of lean mass and grip strength. This rapid change in weight may require cystic fibrosis patients to adapt their nutritional management and physical activity.
Disclosure of Interest: None declared